2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-137973
    RP-1859 1307869-95-9 98%
    RP-1859 is a sphingosine 1-phosphate receptor (S1P) modulator. RP-1859 exerts anti-inflammatory and immunomodulatory activities. RP-1859 can be used for the research of iatrogenic autoimmune colitis.
    RP-1859
  • HY-137988
    Palvanil 69693-13-6 98.01%
    Palvanil is a Capsaicin (HY-10448) analogue, shows strong desensitizing capability against the TRPV1 receptor. Palvanil shows anti-nociceptive and anti-inflammation effects.
    Palvanil
  • HY-138050
    Nyasol 96895-25-9 98%
    Nyasol ((-)-Nyasol) is an active compound that has antifungal, antibacterial, antileishmanial, hyaluronidase inhibition activities. Nyasol inhibits LTB4 binding to human neutrophils. Nyasol suppresses neuroinflammatory response through the inhibition of I-κB degradation in LPS (HY-D1056)-stimulated BV-2 microglial cells.
    Nyasol
  • HY-138101
    Desmethyl etoricoxib 202409-31-2 99.64%
    Desmethyl etoricoxib (example 21) is a selective COX-2 inhibitor with an IC50 of 1 μM in whole blood. Desmethyl etoricoxib inhibits COX-1 with an IC50 of 16 μM in U937 cells. Desmethyl etoricoxib has anti-inflammatory effects.
    Desmethyl etoricoxib
  • HY-138244
    8-iso Prostaglandin F2β 177020-26-7 98%
    8-iso Prostaglandin F2β (8-iso PGF2β) is a biomarker for assessing oxidative stress, and its content in serum can indirectly reflect the level of oxidative stress.
    8-iso Prostaglandin F2β
  • HY-138284
    Avenanthramide-C methyl ester 955382-52-2 98%
    Avenanthramide-C methyl ester is an anti-inflammatory agent and NF-κB inhibitor that inhibits the secretion of pro-inflammatory factors. Avenanthramide-C methyl ester inhibits NF-κB activation by inhibiting IKK and IκB phosphorylation and inhibiting proteasome activity.
    Avenanthramide-C methyl ester
  • HY-13838A
    PLX647 dihydrochloride 1779796-38-1 98%
    PLX647 dihydrochloride is an orally active, highly specific dual FMS and KIT kinase inhibitor, with IC50s of 28 and 16 nM, reapectively. PLX647 dihydrochloride shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC50s=91 and 130 nM, respectively).
    PLX647 dihydrochloride
  • HY-138454
    MEG hemisulfate 3979-00-8 98%
    MEG (Mercaptoethylguanidine) hemisulfate is a potent and selective inhibitor of the inducible NO synthase (iNOS), with EC50s of 11.5, 110, and 60 μM for iNOS, ecNOS, and bNOS respectively in tissue homogenates. MEG hemisulfate is also a potent scavenger of peroxynitrite and inhibits peroxynitrite-induced oxidative processes. MEG hemisulfate has a protective effect in many experimental models of inflammation, including ischemia/reperfusion injury, periodontitis, hemorrhagic shock, inflammatory bowel disease, and endotoxic and septic shock.
    MEG hemisulfate
  • HY-138616
    dGTP 2564-35-4 98%
    dGTP (2'-Deoxyguanosine-5'-triphosphate) is one of the precursors for DNA synthesis, and serves as a direct substrate for DNA replication and repair. dGTP is prone to oxidative damage; under the action of reactive oxygen species and other factors, dGTP is oxidized to form 8-oxo-dGTP.
    dGTP
  • HY-138623
    GSK789 2540591-06-6 98%
    GSK789 is a selective inhibitor of BET BD1. GSK789 inhibits the growth of leukemia cell lines. GSK789 inhibits LPS-stimulated production of MCP-1, TNFα and IL-6 in human whole blood. GSK789 exhibits antiproliferative, anti-inflammatory and immunomodulatory activities. GSK789 can be used in research related to cancers such as leukemia, as well as inflammatory and immune diseases.
    GSK789
  • HY-138651
    PAB-Val-Lys-Boc 1432969-86-2
    PAB-Val-Lys-Boc is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) for stimulating an immune response.
    PAB-Val-Lys-Boc
  • HY-138871
    cPLA2α-IN-derivative 1 1233706-89-2 98%
    cPLA2α-IN-derivative 1 is an inactive alcohol derivative of a highly potent Cytosolic phospholipase A2α (cPLA2α) inhibitor.
    cPLA2α-IN-derivative 1
  • HY-138942
    PF-06427878 1809064-23-0 98%
    PF-06427878 is an orally active, selective liver-targeted diacylglycerol acyltransferase 2 (DGAT2) inhibitor with IC50s of 99 nM and 202 nM for human and rat DGAT2, respectively. PF-06427878 shows greater than 470-fold selectivity for DGAT2 over DGAT1, MGAT1, MGAT2 and MGAT3. PF-06427878 can improve liver steatosis and function. PF-06427878 can be used for the study of nonalcoholic fatty liver diseases.
    PF-06427878
  • HY-138951
    AY77 1835734-92-3 98%
    AY77 is a calcium-biased PAR2 agonist. AY77 shows an EC50 of 0.17 and 2 nM in PAR2-mediated the activation in the Gq pathway and recruitment of β-arrestin-2, respectively. AY77 potently induces intracellular Ca2+ release.
    AY77
  • HY-138990
    GK563 2351820-19-2 98%
    GK563 is a selective Ca2+-independent phospholipase A2 (GVIA iPLA2) inhibitor with an IC50 value of 1 nM. GK563 is 22000 times more active against GVIA iPLA2 than GIVA cPLA2. GK563 reduces β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes.
    GK563
  • HY-139019
    ACAT-IN-2 199984-55-9 98%
    ACAT-IN-2 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 187. ACAT-IN-2 inhibits NF-κB mediated transcription.
    ACAT-IN-2
  • HY-139020
    ACAT-IN-3 454203-25-9 98%
    ACAT-IN-3 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-3 inhibits NF-κB mediated transcription.
    ACAT-IN-3
  • HY-139021
    ACAT-IN-4 454203-56-6 98%
    ACAT-IN-4 (Example 208) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-4 inhibits NF-κB mediated transcription.
    ACAT-IN-4
  • HY-139022
    ACAT-IN-5 199983-93-2 98%
    ACAT-IN-5 (example 19) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-5 inhibits NF-κB mediated transcription.
    ACAT-IN-5
  • HY-139023
    ACAT-IN-6 454203-45-3 98%
    ACAT-IN-6 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 200. ACAT-IN-6 potently inhibits NF-κB mediated transcription.
    ACAT-IN-6
Cat. No. Product Name / Synonyms Application Reactivity